Abstract
Abstract 5259
In this study, we attempted to determine the performance of the soluble fibrin monomer complex (SFMC) test in comparison to known activation markers, such as prothrombin fragment 1.2 (PF1.2), thrombin antithrombin complex (TAT) and d-dimer (DD). We have used the STA(R)-Liatest FM and STA(R)-Liatest D-Di kits to measure the SFMC and d-dimer levels.
A total of 25 patients were included in this study. The data and demographic information are shown in the table below.
| ID . | GENDER . | AGE . | FM . | TAT . | PF1.2 . | D-dimer . |
|---|---|---|---|---|---|---|
| 1 | M | 66 | 0.42 | 2.3 | 1988 | 0.05 |
| 2 | F | 31 | 27.93 | >60.0 | >12000 | 2.39 |
| 3 | F | 24 | 3.41 | 14.1 | 1367 | 0.48 |
| 4 | F | 61 | 2.22 | 7.7 | 335 | 0.63 |
| 5 | F | 18 | 4.61 | 6.9 | 940 | 0.22 |
| 6 | F | 38 | 156.52 | 43.5 | >12000 | 10.37 |
| 7 | F | 20 | 0.42 | 2.2 | 149 | 0.66 |
| 8 | F | 21 | 0.42 | 2.4 | 143 | 0.24 |
| 9 | M | 44 | >150 | 15.4 | 11043 | 5.5 |
| 10 | F | 42 | 3.4 | <2.0 | 134 | 0.24 |
| 11 | M | 46 | 0 | 4.8 | 271 | 0.3 |
| 12 | M | 76 | 90.73 | 29.4 | 1712 | >20.0 |
| 13 | F | 61 | 3.41 | 3.8 | 484 | 0.52 |
| 14 | M | 1 | 0.1 | 3.8 | 116 | 0.33 |
| 15 | F | 33 | 4.2 | 37 | 6346 | 2.03 |
| 16 | F | 35 | 3.2 | 2.6 | 325 | 0.09 |
| 17 | F | 23 | 1.1 | 4.7 | 232 | 0.2 |
| 18 | M | 64 | 2.3 | 2.6 | 189 | 0.15 |
| 19 | M | 1 | 1.7 | 2.9 | 253 | 0.49 |
| 20 | M | 64 | 2.2 | 33.2 | 451 | 2.43 |
| 21 | M | 60 | 1.6 | 2.9 | 126 | 0.42 |
| 22 | F | 55 | 2.2 | 2.6 | 189 | 0.97 |
| 23 | F | 65 | 1.3 | 2.3 | 79 | 0.25 |
| 24 | F | 39 | 3.6 | 8.1 | 222 | 0.18 |
| 25 | M | 2 | 4.8 | <2.0 | 109 | 0.53 |
| Reference | range | >6.0 ug/mL | <4 mcg/L | 41–372 pmol/L | <0.45 ug/mL |
| ID . | GENDER . | AGE . | FM . | TAT . | PF1.2 . | D-dimer . |
|---|---|---|---|---|---|---|
| 1 | M | 66 | 0.42 | 2.3 | 1988 | 0.05 |
| 2 | F | 31 | 27.93 | >60.0 | >12000 | 2.39 |
| 3 | F | 24 | 3.41 | 14.1 | 1367 | 0.48 |
| 4 | F | 61 | 2.22 | 7.7 | 335 | 0.63 |
| 5 | F | 18 | 4.61 | 6.9 | 940 | 0.22 |
| 6 | F | 38 | 156.52 | 43.5 | >12000 | 10.37 |
| 7 | F | 20 | 0.42 | 2.2 | 149 | 0.66 |
| 8 | F | 21 | 0.42 | 2.4 | 143 | 0.24 |
| 9 | M | 44 | >150 | 15.4 | 11043 | 5.5 |
| 10 | F | 42 | 3.4 | <2.0 | 134 | 0.24 |
| 11 | M | 46 | 0 | 4.8 | 271 | 0.3 |
| 12 | M | 76 | 90.73 | 29.4 | 1712 | >20.0 |
| 13 | F | 61 | 3.41 | 3.8 | 484 | 0.52 |
| 14 | M | 1 | 0.1 | 3.8 | 116 | 0.33 |
| 15 | F | 33 | 4.2 | 37 | 6346 | 2.03 |
| 16 | F | 35 | 3.2 | 2.6 | 325 | 0.09 |
| 17 | F | 23 | 1.1 | 4.7 | 232 | 0.2 |
| 18 | M | 64 | 2.3 | 2.6 | 189 | 0.15 |
| 19 | M | 1 | 1.7 | 2.9 | 253 | 0.49 |
| 20 | M | 64 | 2.2 | 33.2 | 451 | 2.43 |
| 21 | M | 60 | 1.6 | 2.9 | 126 | 0.42 |
| 22 | F | 55 | 2.2 | 2.6 | 189 | 0.97 |
| 23 | F | 65 | 1.3 | 2.3 | 79 | 0.25 |
| 24 | F | 39 | 3.6 | 8.1 | 222 | 0.18 |
| 25 | M | 2 | 4.8 | <2.0 | 109 | 0.53 |
| Reference | range | >6.0 ug/mL | <4 mcg/L | 41–372 pmol/L | <0.45 ug/mL |
The data indicate that in 16 out 25 patients, the SFMC levels are correlated with TAT and PF1.2. Only 3 out of 25 patients have elevated TAT and PF1.2 with normal SFMC levels. Therefore, our data would tend to indicate that SFMC level could be used as an activation marker to assess an ongoing prothrombotic process. In order to more fully determine the efficacy of the SFMC assay, we will obtain a detailed clinical history for the cases shown above.
No relevant conflicts of interest to declare.
Author notes
Asterisk with author names denotes non-ASH members.
